4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-23-026515
Chief Scientific Officer sold 1,136 shares at $9.88 ($11,219)
- Chief Scientific Officer acquired 3,206 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-30 | Exercise or conversion : show line 1 in the form | +3,206 | 27,768 | D | ||
| 2023-05-01 | Sale : show line 2 in the form | −1,136 | $9.88 | $11,219 | 26,632 | D |
| Open-market sales · 1,136 sh · avg $9.88 · $11,219 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-04-30 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −3,206 | 35,275 | D |
Loading xslF345X04/doc4.xml…